Replies to post #20320 on Mymetics Corp (MYMX)

[bow-tie]

New Results
Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1) Formulated with Alum Induces Protective Immunity and Reduces Immune Enhancement
Wen-Hsiang Chen, Xinrong Tao, Bi-Hung Peng, Jeroen Pollet, Ulrich Strych, Maria Elena Bottazzi, Peter J. Hotez, Sara Lustigman, Lanying Du, Shibo Jiang, Chien-Te K. Tseng
doi: https://doi.org/10.1101/2020.05.15.098079

https://www.biorxiv.org/content/10.1101/2020.05.15.098079v1

Wait mymx using the 3 second lozenges under the tongue for Covid Vaccine with Baylor!! :) For poor countries, Can be shipt in a box.

[Work Harder]

He did @ Pevion

http://www.imvacs.com/imvacs_content.aspx?id=114849

Vaccine Quality throughout the Life Cycle – Speaker Bios

Mario Amacker, Ph.D., Head, Process Development and Manufacturing, Pevion Biotech AG

Mario Amacker joined Pevion Biotech AG (Ittigen, Switzerland) in 2003 as a group leader of the development of virosome-based formulations. In July 2009, he was appointed to the position of Head of Process Development and Manufacturing. Prior to joining Pevion, he was project manager at Gnothis SA (Lausanne, Switzerland) and responsible for the development of enzymes used in single-molecular sequencing by fluorescence correlation spectroscopy. From 1998 to 2000 he held a post-doc position at the Swiss Cancer Research Institute (ISREC, Epalinges, Switzerland) and performed basic research on human telomerase. Mario Amacker holds a PhD in Biochemistry from the University of Zurich (Switzerland) and a Master’s degree in Biochemistry and Molecular Biology from the Swiss Federal Institute of Technology.

CHI